+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Central Nervous System Drugs Market Research Reports

5-HT2C Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT2C Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Bruton's Tyrosine Kinase (BTK) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dementia With Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia With Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025 - Product Thumbnail Image

Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Cataplexy - Pipeline Insight, 2025 - Product Thumbnail Image

Cataplexy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Spinal Cord Injury - Pipeline Insight, 2025 - Product Thumbnail Image

Spinal Cord Injury - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Sturge-Weber Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Sturge-Weber Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Trigeminal Neuralgia- Pipeline Insight, 2025 - Product Thumbnail Image

Trigeminal Neuralgia- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Excessive Daytime Sleepiness - Pipeline Insight, 2025 - Product Thumbnail Image

Excessive Daytime Sleepiness - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Small Fiber Neuropathy - Pipeline Insight, 2025 - Product Thumbnail Image

Small Fiber Neuropathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Traumatic Encephalopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Traumatic Encephalopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Refractory Status Epilepticus - Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Status Epilepticus - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Lou Gehrig's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Lou Gehrig's Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Refractory Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Refractory Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Tay-Sachs Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Tay-Sachs Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 240 Pages
  • Global
From
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
GABAA Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

GABAA Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Loading Indicator

The Central Nervous System Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs that target the central nervous system. These drugs are used to treat a variety of conditions, including neurological disorders, mental health issues, and pain management. The market is composed of a variety of companies, ranging from large multinationals to small start-ups. The Central Nervous System Drugs market is highly competitive, with companies competing to develop the most effective and safe treatments. Companies in the market are constantly researching and developing new drugs, as well as improving existing treatments. Many of these companies are also involved in clinical trials to test the safety and efficacy of their products. Some of the major companies in the Central Nervous System Drugs market include Pfizer, GlaxoSmithKline, Merck, Novartis, and Johnson & Johnson. These companies are involved in the development and production of a wide range of CNS drugs, including antidepressants, antipsychotics, and anticonvulsants. Show Less Read more